Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

PHASE2

Phase

COMPLETED

Status

601

Enrollment

INDUSTRY

Sponsor class

Conditions

BIOLOGICAL: MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine
BIOLOGICAL: Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1
BIOLOGICAL: Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine
BIOLOGICAL: Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1
BIOLOGICAL: Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
BIOLOGICAL: MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine

Novartis Vaccines